
Opinion|Videos|April 7, 2025
Overview of the Biologics Approved in Atopic Dermatitis
Panelists discuss how the current biologic landscape for atopic dermatitis includes 4 distinct agents with complementary mechanisms: dupilumab targeting IL-4 and IL-13 pathways to broadly inhibit type 2 inflammation, lebrikizumab and tralokinumab both selectively blocking IL-13 to potentially offer similar efficacy with refined targeting, and nemolizumab uniquely addressing the IL-31 “itch cytokine” pathway—each representing different strategic approaches to modulating the complex immunopathology of the disease with specific advantages for different patient phenotypes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- We’ll go into more detail in a bit, but can you provide a brief introduction of the biologics currently approved for atopic dermatitis, including how they differ in their mechanisms of action?
- Dupilumab (IL-4/IL-13 inhibitor)
- Lebrikizumab (IL-13 inhibitor)
- Tralokinumab (IL-13 inhibitor)
- Nemolizumab (IL-31 inhibitor)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Freenome Blood Test for Colorectal Cancer Screening
2
FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years
3
Q&A: How to Optimize Pediatric Hypertension Diagnosis and Treatment
4
Where Psoriasis and PsA Care Stand Today: Burden and Unmet Needs
5












































































